Table 3.

Nutritional/functional, laboratory, and quality of life variables evaluated after 1, 2, and 4 months of treatment on 39 patients

VariablesBaseline1 moP2 moP4 moP
Body weight (kg)55.1 ± 1056.5 ± 10.50.00156.4 ± 9.70.03657 ± 9.80.031
LBM (kg)38 ± 938.9 ± 90.05939.4 ± 8.90.04539.7 ± 8.70.024
Grip strength (kg)28.0 ± 10.427.8 ± 9.50.87927.9 ± 9.30.67328.1 ± 9.50.827
Appetite5.5 ± 2.56.6 ± 2.20.0056.8 ± 1.90.0017.0 ± 1.60.004
IL-6 (pg/mL)12.5 ± 9.98.8 ± 8.70.0027.5 ± 8.60.0037.4 ± 8.50.007
TNF-α (pg/mL)22.2 ± 16.619.5 ± 160.20415.8 ± 130.02014 ± 11.70.015
Leptin (ng/mL)5.9 ± 6.18.9 ± 10.60.00810.2 ± 13.30.03113.6 ± 13.3<0.001
ROS (FORT U)468.5 ± 97.2436.6 ± 92.50.033437.7 ± 89.60.087444.1 ± 93.60.162
GPx (units/L)8,206.6 ± 2,322.38,339.3 ± 2,411.80.7268,295.9 ± 2,314.10.8488,849.2 ± 2,6290.211
Quality of life questionnaires
    EORTC QLQ-C3065.9 ± 16.372.4 ± 15.60.00871.8 ± 14.60.02070.9 ± 14.60.044
    EQ-5Dindex0.50 ± 0.40.58 ± 0.40.1750.56 ± 0.40.3400.59 ± 0.40.114
    EQ-5DVAS49.4 ± 21.458.9 ± 22.70.01658.6 ± 20.60.01558.7 ± 19.40.009
    MSFI-SF20.1 ± 22.114.4 ± 20.30.12511.8 ± 17.20.02210.8 ± 14.40.004
  • NOTE: Data are reported as mean ± SD. As for EORTC QLQ-C30, EQ-5D index, and EQ-5DVAS, the increasing of score corresponds to improvement of quality of life, whereas for MSFI-SF, the decrease of quality of life score corresponds to amelioration of fatigue. Significance was considered for P < 0.05 as calculated with Student's t test for paired data (posttreatment values versus baseline values). Significance for IL-6, TNF-α, and leptin was calculated using Wilcoxon ranks test.

    Abbreviations: GPx, glutathione peroxidase; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer QLQ-C30; EQ-5D, Euro QL-5D; MSFI-SF, multidimensional fatigue symptom inventory-short form.